Skip to main content

Drug Interactions between lenalidomide and Pravachol

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

pravastatin lenalidomide

Applies to: Pravachol (pravastatin) and lenalidomide

MONITOR CLOSELY: The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but may involve additive pharmacodynamic effects. The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) evaluated 23 cases of rhabdomyolysis associated with lenalidomide; concomitant use of statins occurred in 4 cases. All cases were considered serious and patients recovered after both drugs were discontinued. Rhabdomyolysis occurred within 5, 14 and 19 days after initiation of lenalidomide in 3 cases and within 8 days after increased lenalidomide dosage in the fourth case.

MANAGEMENT: European product labeling recommends caution and increased clinical and biological monitoring if lenalidomide is used in combination with statins, especially during the first several weeks of treatment. All patients treated with statins should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
  3. EMA. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) (2014) Revlimid. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/000717/WC500160159.pdf
  4. EMA. European Medicines Agency. PRAC. Pharmacovigilance Risk Assessment Committee (2014) Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 2-5 September 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2013/10/WC500152672.pdf
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

pravastatin food

Applies to: Pravachol (pravastatin)

MONITOR: Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury. Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury. Active liver disease or unexplained transaminase elevations are contraindications to statin use.

MANAGEMENT: Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.

References

  1. (2001) "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb
  2. (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
  3. (2001) "Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals
  4. (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
  5. (2002) "Product Information. Altocor (lovastatin)." Andrx Pharmaceuticals
  6. (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
  7. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  8. Cerner Multum, Inc. "Australian Product Information."
  9. (2010) "Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)
View all 9 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer